{"schema_version":"1.0","type":"article","title":"減肥藥之王 78億美元，買下一個「清醒時代」？","url":"https://drugnews.com.tw/articles/2026-04-13-78.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-13-78.md","lang":"zh-Hant","date":"2026-04-13","publish_at":"2026-04-13T10:30:00+08:00","updated_at":"2026-04-13","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI","GLP-1","BD","臨床數據","生技投資"],"summary":"當 Eli Lilly（禮來） 以最高 78 億美元 收購 Centessa Pharmaceuticals，這筆交易表面上看，是大藥廠再一次用高溢價把一條中期臨床資產收入囊中；但若把時間線再拉長一點，它其實更像是一場很有方向感的提前卡位。","key_points":[],"facts":[],"sections":["禮來重押睡眠與 OX2R 賽道","一場不是單純追價的併購","為什麼 Centessa 值得這個價？","為什麼 OX2R 這麼吸引人？","這其實也是一筆很典型的 Lilly 式交易","但這不是沒有對手的藍海","所以，Lilly 到底買到了什麼？"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders","source":"","date":"","url":""},{"title":"/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines...","source":"","date":"","url":""},{"title":"www.prnewswire.com","source":"","date":"","url":""},{"title":"\"Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders\"","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"FDA Approves First Medication for Obstructive Sleep Apnea","source":"FDA","date":"","url":""},{"title":"Today, the FDA approved the first medication for the treatment of moderate to severe obstructive sleep apnea in adults with obesity, to be used in combination with a reduced-calorie diet and increased physical activity.","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/legal/transactional/eli-lilly-buy-centessa-pharma-63-billion-deal-2026-03-31/","source":"","date":"","url":"https://www.reuters.com/legal/transactional/eli-lilly-buy-centessa-pharma-63-billion-deal-2026-03-31/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program - BioSpace","source":"","date":"","url":""},{"title":"https://www.biospace.com/press-releases/centessa-pharmaceuticals-reports-financial-results-for-the-third-quarter-of-2025-and-provides-update-on-potential-best-in-class-orexin-receptor-2-ox2r-agonist-program","source":"","date":"","url":"https://www.biospace.com/press-releases/centessa-pharmaceuticals-reports-financial-results-for-the-third-quarter-of-2025-and-provides-update-on-potential-best-in-class-orexin-receptor-2-ox2r-agonist-program"},{"title":"www.biospace.com","source":"","date":"","url":""},{"title":"\"Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program - BioSpace\"","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"YouTube","source":"","date":"","url":""},{"title":"The FDA has accepted Takeda’s NDA and granted Priority Review for Oveporexton (TAK‑861), a potential first‑in‑class treatment for Narcolepsy Type 1.","source":"","date":"","url":""},{"title":"www.takeda.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：減肥藥之王 78億美元，買下一個「清醒時代」？（圖 1）","url":"https://drugnews.com.tw/assets/articles/78/dcard-01.webp"},{"alt":"Dcard 原圖：減肥藥之王 78億美元，買下一個「清醒時代」？（圖 2）","url":"https://drugnews.com.tw/assets/articles/78/dcard-02.webp"},{"alt":"Dcard 原圖：減肥藥之王 78億美元，買下一個「清醒時代」？（圖 3）","url":"https://drugnews.com.tw/assets/articles/78/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/78/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-13）。減肥藥之王 78億美元，買下一個「清醒時代」？。https://drugnews.com.tw/articles/2026-04-13-78.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-13-78-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}